🇺🇸 SECNOVO NORDISK A SQwen · 实盘不做把握 1/10不做原因:无增量信息
北京时间·🕒 发布 21:11:30·⟳ 抓取 21:11:57 +27s·⚡ 决策 08-31 21:23:54 +11m57s·57.0 天前
Novo Nordisk 6-K 例行披露股票回购进度：已按计划回购DKK 87亿，无新增信息
这是Novo Nordisk已公布7个月的DKK 150亿回购计划的例行进度更新（8月25-28日每日21万股），属于MAR Safe Harbour合规披露。无计划规模变更、无加速/减速信号、无新信息。市场早已将该回购计划纳入定价，任何额外研究（行情、先例、供应链）都不可能改变'不做'的结论。
📄 原文NOVO NORDISK A S↗ 原文
----- f6k_083126.htm ----- 6-K 1 f6k_083126.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 Novo Nordisk（NVO.US）
例行回购进度报告（6-K），回购计划已于2026年2月公布并持续执行近7个月，本次仅披露8月25-28日每日21万股的常规交易明细，无计划变更、无加速信号、无新增信息，不构成可交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Novo Nordisk于2026年2月4日公布DKK 150亿回购计划，5月6日启动当前批次。本次6-K仅报告8月25-28日5个交易日各21万股的常规回购（日均约DKK 6300万），累计执行58%。文件无任何计划变更、加速信号或新增信息，纯属监管合规进度报告。回购计划本身已被市场充分定价近7个月，不构成可交易催化。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 low · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:无需先例：事件本身不含增量信息，不存在可交易的催化
方向:无先例可查——例行回购进度报告本身不构成事件类型，历史上不产生可测量的价格反应
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 717 ms
{"result": "search_processed_events:agent query=`novo nordisk dkk 15 billion repurchase | novo nordisk share repurchase programme | nvo buyback 6-k`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、1169 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 4,153 字
----- f6k_083126.htm -----
6-K
1
f6k_083126.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 31, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 31 August 2026 –
On 6 May 2026, Novo
Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and
Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").
This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning
4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares
for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 24 August, the following transactions have been made:
Number
of
B
shares
Average
purchase
price
Transaction
value,
DKK
Accumulated, last announcement
15,170,000
4,590,476,842
24 August 2026
210,000
301.87
63,393,359
25 August 2026
210,000
306.00
64,259,374
26 August 2026
210,000
308.60
64,805,405
27 August 2026
210,000
296.89
62,346,025
28 August 2026
210,000
297.11
62,392,810
Accumulated under the programme
16,220,000
4,907,673,815
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 45,019,876 B shares of DKK
0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is
4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion
during a 12-month period beginning 4 February 2026. As of 28 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 30,979,179
B shares at an average share price of DKK 281.08 per B share equal to a transaction value of DKK 8,707,673,805.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Alex Bruce
Ida Schaap Melvold
+45 3444 2613
+45 3077 5649
axeu@novonordisk.com
idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin
Mads Berner Bruun
+45 3079 1471
+45 3075 2936
cftu@novonordisk.com
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 53 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 31, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer
6-K
1
f6k_083126.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 31, 2026
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F ☒
Form 40-F ☐
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 31 August 2026 –
On 6 May 2026, Novo
Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and
Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").
This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning
4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares
for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 24 August, the following transactions have been made:
Number
of
B
shares
Average
purchase
price
Transaction
value,
DKK
Accumulated, last announcement
15,170,000
4,590,476,842
24 August 2026
210,000
301.87
63,393,359
25 August 2026
210,000
306.00
64,259,374
26 August 2026
210,000
308.60
64,805,405
27 August 2026
210,000
296.89
62,346,025
28 August 2026
210,000
297.11
62,392,810
Accumulated under the programme
16,220,000
4,907,673,815
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 45,019,876 B shares of DKK
0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is
4,465,000,000 including treasury shares.
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion
during a 12-month period beginning 4 February 2026. As of 28 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 30,979,179
B shares at an average share price of DKK 281.08 per B share equal to a transaction value of DKK 8,707,673,805.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
and YouTube.
Contacts for further information
Media:
Ambre James-Brown
Liz Skrbkova (US)
+45 3079 9289
+1 609 917 0632
globalmedia@novonordisk.com
USMediaRelations@novonordisk.com
Investors:
Michael Novod
Sina Meyer
+45 3075 6050
+45 3079 6656
nvno@novonordisk.com
azey@novonordisk.com
Alex Bruce
Ida Schaap Melvold
+45 3444 2613
+45 3077 5649
axeu@novonordisk.com
idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin
Mads Berner Bruun
+45 3079 1471
+45 3075 2936
cftu@novonordisk.com
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Novo Nordisk A/S
Investor Relations
Novo Allé 1
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
www.novonordisk.com
CVR no: 24 25 67 90
Company
announcement No 53 / 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 31, 2026
NOVO NORDISK A/S
Maziar Mike Doustdar
Chief Executive Officer
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。